PTIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PTIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Protagenic Therapeutics's change in inventory for the quarter that ended in Sep. 2024 was $0.00 Mil. It means Protagenic Therapeutics's inventory stayed the same from Jun. 2024 to Sep. 2024 .
Protagenic Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Protagenic Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .
Protagenic Therapeutics's Total Inventories for the quarter that ended in Sep. 2024 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Protagenic Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagenic Therapeutics Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Protagenic Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagenic Therapeutics (NAS:PTIX) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Protagenic Therapeutics's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= | N/A |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Protagenic Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Protagenic Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Protagenic Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander K. Arrow | officer: Chief Financial Officer | PO BOX 3094, REDWOOD CITY CA 94064 |
Jennifer Buell | director | 3 FORBES ROAD, LEXINGTON MA 02421 |
Brian Corvese | director | C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010 |
Robert Benjamin Stein | director | C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421 |
Khalil Barrage | director | 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010 |
Gregory Ekizian | director | 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010 |
Robert Ziroyan | officer: COO / Interim President | 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010 |
Joshua Silverman | director | IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
Garo H Armen | director, 10 percent owner, officer: See Remarks | 3 FORBES ROAD, LEXINGTON MA 02421 |
Edward J Gildea | director, officer: Chief Executive Officer | C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110 |
David J Horin | officer: Chief Financial Officer | 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020 |
Jonathan Schechter | director | C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165 |
Nathan Yu-gai Fong | officer: Chief Financial Officer | THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003 |
Sharon Siegel | officer: Chief Marketing Officer | C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018 |
Raymond Musci | director, officer: Exec VP, Corporate Development | C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367 |
From GuruFocus
By Marketwired Marketwired • 06-16-2021
By Marketwired Marketwired • 06-11-2018
By GuruFocus Research • 03-05-2024
By ACCESSWIRE • 04-17-2024
By GuruFocus Research • 04-02-2024
By ACCESSWIRE • 11-05-2024
By ACCESSWIRE • 12-12-2023
By Marketwired Marketwired • 09-08-2020
By GuruFocus Research • 03-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.